Overview

A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease

Status:
Completed
Trial end date:
2000-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions